These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 15500435)
41. IIb/IIIa or not IIb/IIIa? That is the question. Redwood S Int J Clin Pract; 1999 Dec; 53(8):577. PubMed ID: 10692749 [No Abstract] [Full Text] [Related]
42. Platelet GPIIb/IIIa receptor antagonists in human ischemic brain disease. Seitz RJ; Siebler M Curr Vasc Pharmacol; 2008 Jan; 6(1):29-36. PubMed ID: 18220937 [TBL] [Abstract][Full Text] [Related]
43. Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams? Montalescot G Eur Heart J; 2004 Sep; 25(18):1562-4. PubMed ID: 15351154 [No Abstract] [Full Text] [Related]
49. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes. Pandey A; Seroogy J; Volkots D; Smyth MS; Rose J; Mehrotra MM; Heath J; Ruhter G; Schotten T; Scarborough RM Bioorg Med Chem Lett; 2001 May; 11(10):1293-6. PubMed ID: 11392540 [TBL] [Abstract][Full Text] [Related]
50. [The history of the SET-UP study (or how difficult is neutrality in clinical research)]. Tavazzi L; Maggioni AP Ital Heart J Suppl; 2000 Apr; 1(4):582-3. PubMed ID: 10832152 [No Abstract] [Full Text] [Related]
51. Relation between inhibition of platelet aggregation and clinical outcomes. Harrington RA; Kleiman NS; Granger CB; Ohman EM; Berkowitz SD Am Heart J; 1998 Oct; 136(4 Pt 2 Su):S43-50. PubMed ID: 9778087 [TBL] [Abstract][Full Text] [Related]
52. Eptifibatide: a cyclic peptide that selectively inhibits platelet glycoprotein IIb/IIIa. Heras M; Escolar G Drugs Today (Barc); 2000 May; 36(5):295-311. PubMed ID: 12861353 [TBL] [Abstract][Full Text] [Related]
53. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes. Mehrotra MM; Heath JA; Rose JW; Smyth MS; Seroogy J; Volkots DL; Ruhter G; Schotten T; Alaimo L; Park G; Pandey A; Scarborough RM Bioorg Med Chem Lett; 2002 Apr; 12(7):1103-7. PubMed ID: 11909727 [TBL] [Abstract][Full Text] [Related]
54. Ha K; Zheng X; Kessinger CW; Mauskapf A; Li W; Kawamura Y; Orii M; Hilderbrand SA; Jaffer FA; McCarthy JR ACS Sens; 2021 Jun; 6(6):2225-2232. PubMed ID: 34056903 [TBL] [Abstract][Full Text] [Related]
55. Glycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis. Hasanpour M; Maleki S; Rezaee H; Aminzadeh B; Abbasi Shaye Z; Keykhosravi E Neuroradiol J; 2024 Apr; 37(2):152-163. PubMed ID: 36961079 [TBL] [Abstract][Full Text] [Related]
56. Effect of salt form on chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms. Badawy SI Int J Pharm; 2001 Jul; 223(1-2):81-7. PubMed ID: 11451634 [TBL] [Abstract][Full Text] [Related]
57. Crystallization of the OP-G2 Fab fragment: a fibrinogen mimic with specificity for the platelet glycoprotein IIb/IIIa. Celikel R; Williamson MM; Ni C; Ely KR Acta Crystallogr D Biol Crystallogr; 1993 Jul; 49(Pt 4):421-2. PubMed ID: 15299517 [TBL] [Abstract][Full Text] [Related]
58. Long-term administration of glycoprotein IIb/IIIa antagonists. Quinn M; Fitzgerald DJ Am Heart J; 1998 May; 135(5 Pt 2 Su):S113-8. PubMed ID: 9588390 [No Abstract] [Full Text] [Related]
60. Lesions and identification of crystalline precipitates of glycoprotein IIb-IIIa antagonists in the rat kidney. Levin S; Friedman RM; Cortez E; Hribar J; Nicholas M; Schlessinger S; Fouant M; Khan N Toxicol Pathol; 1999; 27(1):38-43. PubMed ID: 10367671 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]